Lazard is advising French healthcare group Sanofi on the third-biggest M&A deal announced this year — another early win for Europe's independent investment banks on large-scale transactions in 2018.

Sanofi will pay $11.6bn for US haemophilia treatment specialist Bioverativ, which was spun off by Massachusetts biotech firm Biogen in February 2017.